Average Co-Inventor Count = 6.72
ph-index = 4
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Roche Innovation Center Copenhagen A/s (8 from 46 patents)
2. Hoffmann-la Roche Inc. (5 from 4,948 patents)
3. Santaris Pharma A/s (1 from 44 patents)
4. F. Hoffmann-la Roche Ag (168 patents)
14 patents:
1. 12421516 - Antisense oligomers targeting PCSK9
2. 12259380 - Oligonucleotides for inducing paternal UBE3A expression
3. 11852627 - Oligonucleotides for inducing paternal UBE3A expression
4. 11739332 - Antisense oligomers targeting PCSK9
5. 11320421 - Oligonucleotides for inducing paternal UBE3A expression
6. 11091764 - Antisense oligomers targeting PCSK9
7. 10739332 - Oligonucleotides for inducing paternal UBE3A expression
8. 10718753 - Oligonucleotides for inducing paternal UBE3A expression
9. 10494633 - Oligonucleotides for inducing paternal UBE3A expression
10. 10443058 - Antisense oligomers targeting PCSK9
11. 10385342 - Methods of treatment using antisense oligomers and conjugates targeting PCSK9
12. 10370668 - Manufacture of antisense oligomers and conjugates targeting PCSK9
13. 9879265 - Oligonucleotide conjugates
14. 8580756 - Short oligomer antagonist compounds for the modulation of target mRNA